Developer docs
API playgroundTry for free, no card

Search company profiles

Covis Pharma

Full company profile

uuid00097li

Namestring
Covis Pharma
Legal namestring
Covis Group S.à r.l.
Websiteurl
covispharma.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Covis Pharma is a global specialty pharmaceutical company founded in 2011 that markets established branded therapeutics in 50+ countries for patients with life-threatening and chronic conditions across respiratory, hematology, cardiovascular, and gastroenterology franchises. Its commercial portfolio includes Alvesco and Omnaris (ciclesonide inhaled/intranasal corticosteroids), Tudorza and Duaklir (aclidinium LAMA monotherapy and LAMA/LABA combination delivered via breath-actuated multi-dose dry-powder inhalers), Feraheme (intravenous ferumoxytol for iron deficiency anemia), and legacy cardiovascular and GI brands (Altoprev, Lanoxin, Sular, Prilosec), most of which were acquired over multiple carve-outs from GlaxoSmithKline, AstraZeneca, Sanofi, and Sunovion. The company runs a capital-light operating model, relying on 10+ contract manufacturers (Catalent, Patheon/Thermo Fisher, PCI Pharma) and a network of authorized distributors (Cardinal Health, Chiesi, Menarini, Zentiva, DKSH) to reach markets, supported by direct field sales forces in the United States and major European countries. Revenue is generated through unit-pricing sales of branded and authorized-generic products distributed via wholesale and pharmacy channels, with patient-assistance programs supporting access. The company has also developed ciraparantag, an investigational small-molecule anticoagulant reversal agent, in partnership with Norgine, and demonstrated late-stage clinical development capability through a 1,060-patient Phase 3 COPD trial across multiple Asian markets. In March 2025 Covis became a wholly-owned subsidiary of Azurity Pharmaceuticals, combining 800+ employees and ten dosage forms spanning nine therapeutic areas.

Short descriptiontext

Covis Pharma is a global specialty pharmaceutical company that markets established branded therapeutics across respiratory, hematology, cardiovascular, and gastroenterology franchises in 50+ countries. As of March 2025 it operates as a wholly-owned subsidiary of Azurity Pharmaceuticals.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, respiratory therapies, branded medications, inhalation drug delivery, hospital therapeutics
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Covis Pharma generates revenue through the sale of branded pharmaceutical products across therapeutic areas including respiratory, hematology, cardiovascular, allergy, and gastroenterology. Products are sold directly in major markets and through authorized distributors in 50+ countries. The company also distributes authorized generic versions of select products through partners like Prasco Laboratories.

covispharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Personnel, Technology or R&D, Operations, Others
Pricing details9 tiers
1Altoprev (lovastatin extended-release) WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

20mg: $1,180.62; 40mg: pricing listed; 60mg: pricing listed - per unit WAC as of March 2024

covispharma.com
2Alvesco (ciclesonide) WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

80 MCG/ACT: $274.21; 160 MCG/ACT: pricing listed

covispharma.com
3Duaklir PRESSAIR WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

60 metered doses: $300.00

covispharma.com
4Feraheme (ferumoxytol) WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

510mg 17mL single dose vial: $1,193.62; 10 vials: $11,936.10

covispharma.com
5Lanoxin (digoxin) Injection WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

10 VIAL 2mL: $1,432.26; 10 VIAL 1mL: pricing listed; 10 AMPULE 2mL: $1,377.30; 10 AMPULE 1mL: pricing listed

covispharma.com
6Omnaris (ciclesonide) Nasal Spray WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

50mcg: $294.48

covispharma.com
7Prilosec (omeprazole magnesium) WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

2.5 MG: $452.49; 10 MG: pricing listed

covispharma.com
8Sular (nisoldipine) WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

8.5mg: $3,160.92; 17mg: pricing listed; 34mg: pricing listed

covispharma.com
9Tudorza PRESSAIR WAC pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

400 mcg 30 metered doses: $270.00; 400 mcg 60 metered doses: $450.00

covispharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Covis Pharma is a global specialty pharmaceutical company that markets a portfolio of branded prescription medicines for respiratory, hematology, cardiovascular, gastroenterology, and allergic conditions across more than 50 countries. The company sources products via 10+ contract manufacturing partners and sells them through direct commercial operations in the United States and through authorized distributors (Chiesi, Menarini, Zentiva, Cardinal Health, Novartis, etc.) internationally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Covis Pharma is a global specialty pharmaceutical company that markets therapeutic solutions in 50+ countries for patients with life-threatening conditions and chronic illnesses. The company operates established therapeutic franchises in respiratory, hospital, and specialty care through its portfolio of branded pharmaceutical products. The core product portfolio includes: respiratory treatments (Alvesco, Duaklir, Tudorza for COPD/asthma, and Omnaris for allergic rhinitis); hematology (Feraheme for iron deficiency anemia); cardiovascular (Altoprev statin, Lanoxin cardiac glycoside, Sular calcium channel blocker); and gastroenterology (Prilosec PPI). The company also distributes authorized generics through partners like Prasco Laboratories. Additionally, Covis has development-stage pipeline candidate ciraparantag, an investigational anticoagulant reversal agent being developed in partnership with Norgine. The portfolio was built through strategic acquisitions including rights from AstraZeneca (Alvesco, Omnaris, Zetonna, Eklira/Duaklir) and the acquisition of AMAG Pharmaceuticals (Makena, Feraheme).

Product and service9 records
1Alvesco (ciclesonide)
CategoryRespiratory / Inhaled Corticosteroid
Description

Inhaled glucocorticoid inhalation aerosol for long-term maintenance treatment of asthma in adults and adolescents; small particle size (1-2 micrometers) targets large and small airways.

2Duaklir Pressair (aclidinium bromide and formoterol fumarate)
CategoryRespiratory / LAMA-LABA
Description

Long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) combination for maintenance treatment of COPD, delivered via breath-actuated multi-dose dry powder inhaler (Pressair in US, Genuair elsewhere).

3Tudorza Pressair (aclidinium bromide)
CategoryRespiratory / LAMA
Description

Long-acting muscarinic antagonist (LAMA) for maintenance bronchodilator treatment of COPD, delivered via breath-actuated multi-dose dry powder inhaler (Pressair in US, Genuair elsewhere).

4Feraheme (ferumoxytol)
CategoryHematology / IV Iron
Description

Intravenous iron replacement therapy (510 mg dose) for iron deficiency anemia in adult patients with intolerance to oral iron or with chronic kidney disease.

5Omnaris (ciclesonide nasal spray)
CategoryAllergy / Nasal Corticosteroid
Description

Nasal spray corticosteroid for treatment of allergic rhinitis symptoms.

6Altoprev (lovastatin extended-release)
CategoryCardiovascular / Statin
Description

Extended-release statin tablet for cardiovascular risk reduction and lipid management.

7Lanoxin (digoxin)
CategoryCardiovascular / Cardiac Glycoside
Description

Cardiac glycoside for treatment of heart failure and atrial fibrillation.

8Sular (nisoldipine)
CategoryCardiovascular / Calcium Channel Blocker
Description

Extended-release calcium channel blocker tablet for treatment of hypertension.

9Prilosec (omeprazole magnesium)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Covis acquired global rights to respiratory medicines Alvesco, Omnaris, and Zetonna from AstraZeneca in 2018, and acquired Eklira/Tudorza and Duaklir in 2022 for $270 million. AstraZeneca continues as an ongoing partner for product supply and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract manufacturing organization providing pharmaceutical manufacturing and packaging services for Covis products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract manufacturing organization (part of Thermo Fisher) providing pharmaceutical development and manufacturing services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensor for Tudorza and Duaklir products; original developer of aclidinium bromide and aclidinium/formoterol combination respiratory therapies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract packaging organization providing specialized pharmaceutical packaging solutions.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Operating partner for product distribution and supply chain operations.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Operating partner for manufacturing and product supply.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive Promotion and Distribution Agreement for Seebri Breezhaler and Ultibro Breezhaler in Canada. Covis appointed as exclusive partner to promote and distribute these products in Canada.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Authorized Distributor of Record for Asia-Pacific region.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Authorized Distributor of Record for Europe region.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Authorized Distributor of Record for Europe region.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Authorized Distributor of Record for United States.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Authorized generic distributor for Covis brands including Nisoldipine products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner for ciraparantag, an investigational anticoagulant reversal agent. Norgine co-developed and is collaborating on the ongoing clinical development program for ciraparantag.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Business development partner for product licensing and acquisition opportunities.

16GSK
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Business development partner for product licensing opportunities.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Business development partner for product licensing opportunities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Consumer-focused specialty pharmaceutical company with significant branded and OTC presence including respiratory categories; comparable model of acquiring mature branded assets and operating global commercial/distribution infrastructure.

TypeDirect peer
Description

Specialty pharmaceutical company marketing branded therapies in CNS and oncology; similar model of building through acquisitions of niche marketed assets with global commercial reach and high-margin specialty positioning.

3Endo International
TypeDirect peer
Description

Specialty and generics pharmaceutical company with branded franchises in pain, urology, and endocrinology; comparable business model of acquired specialty assets, complex legal/regulatory history, and PE-era restructuring.

TypeDirect peer
Description

Privately-held global specialty pharmaceutical company with a major respiratory franchise; directly comparable respiratory focus, and also operates as Covis's Asia-Pacific distributor, making it a hybrid peer/distribution partner.

TypeDirect peer
Description

Specialty and generics pharmaceutical company with branded franchises in neurology, endocrinology, and hospital products; comparable combination of branded specialty and authorized-generic distribution model.

6Horizon Therapeutics (now Amgen)
TypeBroad incumbent
Description

Specialty pharmaceutical company focused on rare and inflammatory diseases, recently acquired by Amgen; comparable specialty-pharma acquisition strategy and PE-backed growth model prior to strategic exit.

7Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Global specialty and generics pharmaceutical company with US specialty presence and complex dosage form expertise; comparable global commercial scale, mix of branded specialty and generics, and historical M&A-led portfolio expansion.

TypeDirect peer
Description

European dermatology and respiratory specialty pharmaceutical company; directly comparable respiratory franchise (licensor of Tudorza/Duaklir to Covis) with similar European HQ and focus on inhaled therapies for skin and respiratory conditions.

TypeDirect peer
Description

Specialty pharmaceutical company focused on branded and specialty generics across respiratory, immunology, and hospital products; comparable specialty-pharma model with PE-era ownership, branded legacy portfolio, and similar exposure to legacy-asset regulatory risk.

TypeDirect peer
Description

Specialty pharmaceutical company with diversified branded portfolio across neurology, gastroenterology, dermatology, and eye health; similar PE-driven acquisition strategy, specialty-pharma positioning, and global commercial footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Covis Pharma

Specialty Pharmaceuticalscovispharma.com

Covis Pharma is a global specialty pharmaceutical company that markets established branded therapeutics across respiratory, hematology, cardiovascular, and gastroenterology franchises in 50+ countries. As of March 2025 it operates as a wholly-owned subsidiary of Azurity Pharmaceuticals.

What Covis Pharma does

Covis Pharma is a global specialty pharmaceutical company founded in 2011 that markets established branded therapeutics in 50+ countries for patients with life-threatening and chronic conditions across respiratory, hematology, cardiovascular, and gastroenterology franchises. Its commercial portfolio includes Alvesco and Omnaris (ciclesonide inhaled/intranasal corticosteroids), Tudorza and Duaklir (aclidinium LAMA monotherapy and LAMA/LABA combination delivered via breath-actuated multi-dose dry-powder inhalers), Feraheme (intravenous ferumoxytol for iron deficiency anemia), and legacy cardiovascular and GI brands (Altoprev, Lanoxin, Sular, Prilosec), most of which were acquired over multiple carve-outs from GlaxoSmithKline, AstraZeneca, Sanofi, and Sunovion. The company runs a capital-light operating model, relying on 10+ contract manufacturers (Catalent, Patheon/Thermo Fisher, PCI Pharma) and a network of authorized distributors (Cardinal Health, Chiesi, Menarini, Zentiva, DKSH) to reach markets, supported by direct field sales forces in the United States and major European countries. Revenue is generated through unit-pricing sales of branded and authorized-generic products distributed via wholesale and pharmacy channels, with patient-assistance programs supporting access. The company has also developed ciraparantag, an investigational small-molecule anticoagulant reversal agent, in partnership with Norgine, and demonstrated late-stage clinical development capability through a 1,060-patient Phase 3 COPD trial across multiple Asian markets. In March 2025 Covis became a wholly-owned subsidiary of Azurity Pharmaceuticals, combining 800+ employees and ten dosage forms spanning nine therapeutic areas.

Covis Pharma firmographics

Firmographics
Name
Covis Pharma
Legal name
Covis Group S.à r.l.
Website
https://covispharma.com
Company type
Private
Founded year
2011
Headcount range
251–500 employees
Short description
Covis Pharma is a global specialty pharmaceutical company that markets established branded therapeutics across respiratory, hematology, cardiovascular, and gastroenterology franchises in 50+ countries. As of March 2025 it operates as a wholly-owned subsidiary of Azurity Pharmaceuticals.
Ownership category
akta.pro rank

Covis Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Respiratory therapies
  • Branded medications
  • Inhalation drug delivery
  • Hospital therapeutics

Where Covis Pharma is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices5 records

Markets served

Covis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Covis Pharma generates revenue through the sale of branded pharmaceutical products across therapeutic areas including respiratory, hematology, cardiovascular, allergy, and gastroenterology. Products are sold directly in major markets and through authorized distributors in 50+ countries. The company also distributes authorized generic versions of select products through partners like Prasco Laboratories.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAltoprev (lovastatin extended-release) WAC pricing
Unit PricingPay-as-you-goAlvesco (ciclesonide) WAC pricing
Unit PricingPay-as-you-goDuaklir PRESSAIR WAC pricing
Unit PricingPay-as-you-goFeraheme (ferumoxytol) WAC pricing
Unit PricingPay-as-you-goLanoxin (digoxin) Injection WAC pricing
Unit PricingPay-as-you-goOmnaris (ciclesonide) Nasal Spray WAC pricing
Unit PricingPay-as-you-goPrilosec (omeprazole magnesium) WAC pricing
Unit PricingPay-as-you-goSular (nisoldipine) WAC pricing
Unit PricingPay-as-you-goTudorza PRESSAIR WAC pricing

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Covis Pharma product offering

Product offering

Core offering

Covis Pharma is a global specialty pharmaceutical company that markets a portfolio of branded prescription medicines for respiratory, hematology, cardiovascular, gastroenterology, and allergic conditions across more than 50 countries. The company sources products via 10+ contract manufacturing partners and sells them through direct commercial operations in the United States and through authorized distributors (Chiesi, Menarini, Zentiva, Cardinal Health, Novartis, etc.) internationally.

Product overview

Covis Pharma is a global specialty pharmaceutical company that markets therapeutic solutions in 50+ countries for patients with life-threatening conditions and chronic illnesses. The company operates established therapeutic franchises in respiratory, hospital, and specialty care through its portfolio of branded pharmaceutical products. The core product portfolio includes: respiratory treatments (Alvesco, Duaklir, Tudorza for COPD/asthma, and Omnaris for allergic rhinitis); hematology (Feraheme for iron deficiency anemia); cardiovascular (Altoprev statin, Lanoxin cardiac glycoside, Sular calcium channel blocker); and gastroenterology (Prilosec PPI). The company also distributes authorized generics through partners like Prasco Laboratories. Additionally, Covis has development-stage pipeline candidate ciraparantag, an investigational anticoagulant reversal agent being developed in partnership with Norgine. The portfolio was built through strategic acquisitions including rights from AstraZeneca (Alvesco, Omnaris, Zetonna, Eklira/Duaklir) and the acquisition of AMAG Pharmaceuticals (Makena, Feraheme).

Differentiator

Problem solved

Functional benefit

Products and services

  • Alvesco (ciclesonide) Inhaled glucocorticoid inhalation aerosol for long-term maintenance treatment of asthma in adults and adolescents; small particle size (1-2 micrometers) targets large and small airways.
  • Duaklir Pressair (aclidinium bromide and formoterol fumarate) Long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) combination for maintenance treatment of COPD, delivered via breath-actuated multi-dose dry powder inhaler (Pressair in US, Genuair elsewhere).
  • Tudorza Pressair (aclidinium bromide) Long-acting muscarinic antagonist (LAMA) for maintenance bronchodilator treatment of COPD, delivered via breath-actuated multi-dose dry powder inhaler (Pressair in US, Genuair elsewhere).
  • Feraheme (ferumoxytol) Intravenous iron replacement therapy (510 mg dose) for iron deficiency anemia in adult patients with intolerance to oral iron or with chronic kidney disease.
  • Omnaris (ciclesonide nasal spray) Nasal spray corticosteroid for treatment of allergic rhinitis symptoms.
  • Altoprev (lovastatin extended-release) Extended-release statin tablet for cardiovascular risk reduction and lipid management.
  • Lanoxin (digoxin) Cardiac glycoside for treatment of heart failure and atrial fibrillation.
  • Sular (nisoldipine) Extended-release calcium channel blocker tablet for treatment of hypertension.
  • Prilosec (omeprazole magnesium)

Companies that use Covis Pharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Covis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Covis Pharma partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core and supporting.

  • AstraZenecacoreStrategic or Co-development PartnerCovis acquired global rights to respiratory medicines Alvesco, Omnaris, and Zetonna from AstraZeneca in 2018, and acquired Eklira/Tudorza and Duaklir in 2022 for $270 million. AstraZeneca continues as an ongoing partner for product supply and development.
  • CatalentcoreStrategic or Co-development PartnerContract manufacturing organization providing pharmaceutical manufacturing and packaging services for Covis products.
  • PatheoncoreStrategic or Co-development PartnerContract manufacturing organization (part of Thermo Fisher) providing pharmaceutical development and manufacturing services.
  • AlmirallcoreStrategic or Co-development PartnerLicensor for Tudorza and Duaklir products; original developer of aclidinium bromide and aclidinium/formoterol combination respiratory therapies.
  • PCI PharmacoreStrategic or Co-development PartnerContract packaging organization providing specialized pharmaceutical packaging solutions.
  • Bausch HealthsupportingStrategic or Co-development PartnerOperating partner for product distribution and supply chain operations.
  • TevasupportingStrategic or Co-development PartnerOperating partner for manufacturing and product supply.
  • NovartiscoreChannel Partner/ Reseller/ DistributorExclusive Promotion and Distribution Agreement for Seebri Breezhaler and Ultibro Breezhaler in Canada. Covis appointed as exclusive partner to promote and distribute these products in Canada.
  • ChiesisupportingChannel Partner/ Reseller/ DistributorAuthorized Distributor of Record for Asia-Pacific region.
  • MenarinisupportingChannel Partner/ Reseller/ DistributorAuthorized Distributor of Record for Europe region.
  • ZentivasupportingChannel Partner/ Reseller/ DistributorAuthorized Distributor of Record for Europe region.
  • Cardinal HealthsupportingChannel Partner/ Reseller/ DistributorAuthorized Distributor of Record for United States.
  • Prasco LaboratoriessupportingChannel Partner/ Reseller/ DistributorAuthorized generic distributor for Covis brands including Nisoldipine products.
  • NorginecoreStrategic or Co-development PartnerCo-development partner for ciraparantag, an investigational anticoagulant reversal agent. Norgine co-developed and is collaborating on the ongoing clinical development program for ciraparantag.
  • Acorda TherapeuticssupportingStrategic or Co-development PartnerBusiness development partner for product licensing and acquisition opportunities.
  • GSKsupportingStrategic or Co-development PartnerBusiness development partner for product licensing opportunities.
  • SanofisupportingStrategic or Co-development PartnerBusiness development partner for product licensing opportunities.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Covis Pharma competitors and assessment

Company assessment

Broad incumbents

  • Perrigo Company: Consumer-focused specialty pharmaceutical company with significant branded and OTC presence including respiratory categories; comparable model of acquiring mature branded assets and operating global commercial/distribution infrastructure.
  • Horizon Therapeutics (now Amgen): Specialty pharmaceutical company focused on rare and inflammatory diseases, recently acquired by Amgen; comparable specialty-pharma acquisition strategy and PE-backed growth model prior to strategic exit.
  • Sun Pharmaceutical Industries: Global specialty and generics pharmaceutical company with US specialty presence and complex dosage form expertise; comparable global commercial scale, mix of branded specialty and generics, and historical M&A-led portfolio expansion.

Direct peers

  • Jazz Pharmaceuticals: Specialty pharmaceutical company marketing branded therapies in CNS and oncology; similar model of building through acquisitions of niche marketed assets with global commercial reach and high-margin specialty positioning.
  • Endo International: Specialty and generics pharmaceutical company with branded franchises in pain, urology, and endocrinology; comparable business model of acquired specialty assets, complex legal/regulatory history, and PE-era restructuring.
  • Chiesi Farmaceutici: Privately-held global specialty pharmaceutical company with a major respiratory franchise; directly comparable respiratory focus, and also operates as Covis's Asia-Pacific distributor, making it a hybrid peer/distribution partner.
  • Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with branded franchises in neurology, endocrinology, and hospital products; comparable combination of branded specialty and authorized-generic distribution model.
  • Almirall: European dermatology and respiratory specialty pharmaceutical company; directly comparable respiratory franchise (licensor of Tudorza/Duaklir to Covis) with similar European HQ and focus on inhaled therapies for skin and respiratory conditions.
  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company focused on branded and specialty generics across respiratory, immunology, and hospital products; comparable specialty-pharma model with PE-era ownership, branded legacy portfolio, and similar exposure to legacy-asset regulatory risk.
  • Bausch Health (formerly Valeant Pharmaceuticals): Specialty pharmaceutical company with diversified branded portfolio across neurology, gastroenterology, dermatology, and eye health; similar PE-driven acquisition strategy, specialty-pharma positioning, and global commercial footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Covis Pharma compliance and trust

Trust signal

Compliance1 record

Covis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Covis Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Covis Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Covis Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Covis Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covis Pharma

What does Covis Pharma do?

Covis Pharma is a global specialty pharmaceutical company that markets a portfolio of branded prescription medicines for respiratory, hematology, cardiovascular, gastroenterology, and allergic conditions across more than 50 countries. The company sources products via 10+ contract manufacturing partners and sells them through direct commercial operations in the United States and through authorized distributors (Chiesi, Menarini, Zentiva, Cardinal Health, Novartis, etc.) internationally.

Is Covis Pharma a public or private company?

Covis Pharma is a private company. It is classified as corporate owned.

When was Covis Pharma founded?

Covis Pharma was founded in 2011. It employs 251 to 500 people.

Where is Covis Pharma based?

Covis Pharma is headquartered in Zug, Switzerland, in the Europe region.

How does Covis Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Covis Pharma's main competitors?

Broad incumbents on record are Perrigo Company, Horizon Therapeutics (now Amgen) and Sun Pharmaceutical Industries. Direct peers are Jazz Pharmaceuticals, Endo International, Chiesi Farmaceutici, Amneal Pharmaceuticals, Almirall, Mallinckrodt Pharmaceuticals and Bausch Health (formerly Valeant Pharmaceuticals).

Does Covis Pharma have an API?

No public API is recorded for Covis Pharma.

What industry is Covis Pharma in?

Covis Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAzurity Pharmaceuticals Showcases Growth and Commercial Momentum ahead of CPHI Milan 2026Azurity Pharmaceuticals highlighted its global growth ahead of CPHI Milan 2026, citing a commercial presence in over 50 countries and a portfolio across 11 therapeutic areas. The company's 2025 Covis Pharma acquisition expanded its market reach, and executives will present on medicine design and supply chain at the conference.Eversheds SutherlandEversheds Sutherland advises Azurity Pharmaceuticals on strategic acquisition of Covis Pharma GroupAzurity Pharmaceuticals has completed the strategic acquisition of Covis Pharma Group, expanding its global commercial footprint to over 50 countries. The transaction was advised by Eversheds Sutherland across multiple jurisdictions including the US, Switzerland, and Germany. This move significantly enhances Azurity's product portfolio with more than 50 life-changing treatments across nine key therapeutic areas.PR NewswireGlobal IV & Oral Iron Drugs Market Report 2024: Market to Reach $16.43 Billion by 2029 with CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics DominatingThe global IV and oral iron drugs market, valued at $7.66 billion in 2023, is projected to reach $16.43 billion by 2029, growing at a compound annual growth rate of 13.47%, driven by increasing prevalence of iron deficiency and iron deficiency anemia along with rising chronic diseases such as chronic kidney disease. Key market leaders including CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, and Shield Therapeutics are focusing on strategic acquisitions and collaborations to expand their market presence. The nephrology segment held the largest market share in 2023 at 60.84%, while hospital pharmacies are expected to witness significant growth due to cost-effective drug dispensing services.GlobeNewswireCovis Announces Successful Completion of Its Previously Announced Financial Recapitalization Transaction, Resulting in a Material Strengthening of Its Financial PositionCovis completed its financial recapitalization, reducing debt by approximately $450 million and strengthening its balance sheet. The transaction was supported by 100% of First and Second Lien lenders, with Equity Sponsors remaining majority owners. The company is now positioned to scale organically and pursue inorganic growth.AxiosFDA pulls Makena approval, leaves patients without preterm birth treatmentThe FDA withdrew approval of Covis' Makena, a preterm birth drug, on Thursday, citing lack of evidence of effectiveness. The decision is immediate, leaving patients without the only previously approved treatment for recurrent spontaneous preterm birth. ACOG will update clinical guidance in coming days.BenzingaFDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits - VanEck Biotech ETF (NASDAQ:The FDA announced the final decision to withdraw approval of Covis Pharma's Makena (hydroxyprogesterone caproate injection), a drug approved in 2011 under the accelerated approval pathway to reduce the risk of preterm birth. The withdrawal was triggered after a required post-marketing confirmatory study failed to verify clinical benefit, and an FDA advisory committee voted in October 2022 that the drug should not remain on the market. Effective immediately, Makena and its generics are no longer approved and cannot lawfully be distributed.BenzingaCovis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births - iShares Biotechnology ETPrivately held Covis Pharma announced it is voluntarily withdrawing Makena (hydroxyprogesterone caproate injection) from the US market after an FDA advisory committee voted in October that the drug should not remain on the market because a large post-market study failed to verify clinical benefit. The FDA had been seeking to pull the drug's approval since 2020, concluding that the available evidence does not show Makena is effective for its approved use in reducing the risk of preterm birth. The treatment, originally approved in February 2011 based on a 2003 study showing a 30.7% reduction in recurrent preterm birth, becomes the first FDA-approved treatment for preterm birth prevention to be withdrawn.GlobeNewswireCovis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPDCovis Pharma announced positive topline results from the AVANT phase 3 trial for Duaklir and Eklira in moderate to severe stable COPD. The 24-week study of 1,060 patients showed statistically significant improvements in FEV1 for both drugs versus placebo. The company plans to pursue regulatory approval for broader use.FiercePharmaFDA panel votes to pull Covis' Makena in latest accelerated approval imbroglioAn FDA panel voted 14-1 to pull Covis Pharma's Makena from the market after its 2018 confirmatory trial failed to show it prevented death or complications in newborns. The agency had suggested removal in 2019, and Covis offered additional trials and a partial withdrawal plan.BioSpaceCovis Pharma Reports on FDA Advisory Committee Hearing for Makena®The FDA's Obstetrics, Reproductive, and Urologic Drugs Advisory Committee voted to recommend withdrawal of Makena approval, the only FDA-approved treatment to reduce preterm birth risk in women with prior spontaneous preterm birth. Covis Pharma stated the product remains approved and the label unchanged while awaiting a final FDA decision.